Hypoglycaemia and its consequences

Project Details

In collaboration with Novo Nordisk, Amylin Pharmaceuticals and University of Leicester, Prof. Paul is leading a research project to evaluate the risk factors associated with mild-moderate and severe hypoglycaemia, and the long-term consequences of hypoglycaemia. 

The first real-world based study evaluating the cardiovascular consequences of hypoglycaemia in both type 1 and type 2 diabetes patients was published in Diabetes Care 2015; 38: 316-22. The possible risk factors associated with hypoglycaemia differentiated between patients treated with insulin and incretin-based therapies was published in Journal of Diabetes 2015; 7: 60-7

Researchers

Prof Sanjoy Paul, Director

Collaborators

Professor Kamlesh Khunti, University of Leicester, UK

Funding

Industry grants from Novo Nordisk and Amylin Pharmaceuticals

Research Outcomes

  1. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316-22.
  2. Paul SK, Maggs D, Klein K, Best JH. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly. Journal of diabetes. 2015;7(1):60-7.

Research Group

Melbourne EpiCentre


School Research Themes

Cardiometabolic



Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Medicine and Radiology

Unit / Centre

Melbourne EpiCentre